DOCSLIB.ORG

Concert Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Concert Management CoNCERT Management Roger D. Tung President and Chief Executive Officer Roger D. Tung, Ph.D. is our co-founder and has served as our President and Chief Executive Officer and as a member of our board of directors since April 2006. Before Concert, Dr. Tung was a founding scientist at Ver- tex Pharmaceuticals, a pharmaceutical company, where he was employed from 1989 to 2005, most recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for Medicinal Chemistry. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison. Marc Becker Chief Financial Officer Mr. Marc Becker has served as our Chief Financial Officer since January 2018. Prior to joining Concert, Mr. Becker served as Senior Vice President and Chief Financial Officer at CRISPR Therapeutics from February 2016 to September 2017. Prior to joining CRISPR Therapeutics, Mr. Becker served as Chief Financial Officer and Senior Vice President of rEVO Biologics, a biopharmaceutical from January 2012 to February 2016. Before rEVO, Mr. Becker spent 10 years at Genzyme Corporation, most recently serving as Finance Director for the UK and Ireland before returning to the United States to become the Vice President of Finance for Genzyme’s Renal and Endocrine business. He also serves on the Board of Directors of Food for Free, a non- profit organization in Cambridge, MA. Mr. Becker began his career in auditing and commercial lending for financial services firms, KPMG and BankBoston. Mr. Becker holds a BS from the University of Massachusetts, an MBA from Babson College and was licensed as a CPA. James Cassella Chief Development Officer Dr. James Cassella has served as our Chief Development Officer since February 2015. Prior to joining Con- cert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from June 2004 to January 2015. Prior to Alexza Pharmaceuticals, Dr. Cas- sella held various management positions at Neurogen Corporation, including Senior Vice President, Clinical Research and Development. Before joining the biotechnology industry, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received his Ph.D. in Physiological Psychology from Dart- mouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in psychology from the University of New Haven. Lynette A. Herscha General Counsel Ms. Lynette Herscha has served as our General Counsel and Secretary since June 2017 and was our Vice President and Associate General Counsel from July 2014 to June 2017. Prior to joining Concert, she held senior legal positions at Momenta Pharmaceuticals, Inc., a public biotechnology company, and Phase For- ward, Incorporated, a public technology company. Ms. Herscha began her career at the law offices of Fulbright & Jaworksi. Ms. Herscha earned her J.D. from Boston University School of Law and her B.A. from Boston University. Nancy Stuart Chief Operating Officer Ms. Nancy Stuart has served as our Chief Operating Officer since October 2007 and was our Senior Vice President, Corporate Strategy and Operations from July 2006 to October 2007. Prior to joining Concert Ms. Stuart held various business operations and business development positions at Amgen Inc., a biopharmaceu- tical company, Kinetix Pharmaceuticals, Inc., a pharmaceutical company subsequently acquired by Amgen, Scion Pharmaceuticals, Inc., a pharmaceutical company, Vertex Pharmaceuticals, a pharmaceutical company and Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A. Ms. Stuart holds a B.S. from the University of Michigan, and an M.B.A. from the Simmons College Graduate School of Management. Concert Pharmaceuticals, Inc. │99 Hayden Avenue │ Suite 500 │ Lexington, MA 02421 │ 781.860.0045 │www.concertpharma.com Justine E. Koenigsberg Senior Vice President, Corporate Communications and Investor Relations Ms. Koenigsberg joined Concert in March 2008 and currently serves as Senior Vice President, Corporate Communications and Investor Relations. She has more than 20 years corporate communications and investor relations experience within the biotechnology industry. Prior to joining Concert she held senior communication roles at ViaCell, Inc. and Transkaryotic Therapies (TKT) where she developed and implemented a variety of communication strategies and managed their investor relations programs. Prior to TKT, she held communications positions at Vertex Pharmaceuticals. Ms. Koenigsberg is a member of the National Investors Relations Institute and served on the Board of Directors and as a Past-President of its Boston Chapter. She holds a B.S. in Business Administration from Northeastern University. Virginia Braman Vice President, Clinical Development Ms. Braman joined Concert in April 2010 and currently serves as Vice President, Clinical Development. She has over 25 years of research, development and clinical experience. Prior to Concert, she had a variety of clinical roles across a number of therapeutic areas at Cambridge BioScience, ImmunoGen, Cardiokine, and NitroMed. At NitroMed, she managed the Phase 3 clinical trial for BiDil® for the treatment of heart failure, which led to FDA approval. Prior to joining the biotechnol- ogy industry, Ms. Braman conducted research using monoclonal antibodies at both Beth Israel Hospital in Boston and Uni- versity of Pennsylvania Medical School. Ms. Braman holds a B.S. in Biology from Northeastern University. Christine Boisclair Vice President, Regulatory Affairs Ms. Boisclair joined Concert in June 2016 as Vice President, Regulatory Affairs with more than 30 years Regulatory Affairs experience in the biopharmaceutical industry and across multiple therapeutic areas. Prior to joining Concert, Ms. Boisclair was Vice President, Regulatory Affairs at Forum Pharmaceuticals. Before joining Forum Pharmaceuticals Ms. Boisclair held management roles at several companies including Insmed Inc, Agennix Inc, OSI Pharmaceuticals Inc, Genzyme Corpora- tion, Immulogic Pharmaceuticals and Parexel International. Ms. Boisclair began her regulatory career at Searle Pharma- ceuticals and Glaxo in the UK. She received a Bachelor of Science Honors Degree in Biochemistry from the University of York in the UK. Julie Liu, Ph.D. Vice President, Research and Development Management Dr. Liu joined Concert in January 2007 and currently serves as Vice President, Research and Development Management. She has more than 18 years of experience in the pharmaceutical and biotechnology industry in the fields of medicinal chemistry, research management, and development program management. Prior to joining Concert, Dr. Liu worked at Millennium Pharmaceuticals in the areas of oncology, inflammation, and metabolic disease. She earned her B.S. in Chem- istry with honors and distinction from the University of North Carolina at Chapel Hill, and her Ph.D. in Organic Chemistry from the University of California, Berkeley. Scott Weintraub Vice President, Commercial and Product Strategy Mr. Weintraub joined Concert in August 2016 and currently serves as Vice President, Commercial and Product Strategy. Mr. Weintraub has more than 17 years commercial experience, including strategic product assessment, brand positioning, commercial life cycle management and sales and marketing. Prior to joining Concert he was Vice President of Product Strategy and Marketing at Forum Pharmaceuticals. He also served as Senior Director of Marketing at Sunovion Pharma- ceuticals and held sales and marketing positions at AstraZeneca. He holds a B.S. in Finance and Marketing from Florida State University and an MBA in Health Administration and Policy from University of Miami. Concert Pharmaceuticals and the CoNCERT logo are trademarks of Concert Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. 2 May 2018 .
Load more

Recommended publications
  • National Lipid Association Annual Summary of Clinical Lipidology 2016 Disclosures Dr. Harold E. Bays: Dr. Bays Discloses That He
    National Lipid Association Annual Summary of Clinical Lipidology 2016 Disclosures Dr. Harold E. Bays: Dr. Bays discloses that he has received research grants from Arena Pharmaceuticals, Boehringer Ingelheim, Cargill Inc., GlaxoSmithKline, Novo Nordisk, Orexigen Therapeutics, Shionogi, Takeda, Stratum Nutrition, California Raisin Board, Esperion, Essentialis, Forest, Gilead Sciences Inc., Given, Hoffman-LaRoche, Home Access, Novartis, Omthera, Pfizer, Trygg Pharmaceuticals, TWI Bio, Xoma, Ardea Inc., High Point Pharmaceuticals LLC, Micropharma Limited, TransTech Pharma Inc., TIMI, Pozen, Regeneron, and Elcelyx. He further discloses that he has received honoraria/research grants from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Catabasis, Daiichi-Sankyo Inc., Eisai, Merck & Co, VIVUS, Zeomedex, and WPU. Dr. Peter H. Jones: Dr. Jones has received consulting or speaker honoraria from Merck and Co., Amgen, and Sanofi-Aventis/Regeneron. Dr. W. Virgil Brown: Dr. Brown is the editor of the Journal of Clinical Lipidology and further discloses that he has received consulting fees/honoraria from Akcea, Esperion, Regeneron, Amgen, Genzyme, Pfizer Inc., Merck and Co, GlaxoSmithKline, Medtelligence, and Vindico. Dr. Terry A. Jacobson: Dr. Jacobson has received consulting fees from Merck and Co., Amarin, Amgen, AstraZeneca, and Regeneron/Sanofi-Aventis. Dr. Karen E. Aspry: Dr. Aspry has no disclosures to report. Dr. Christie M. Ballantyne: Dr. Ballantyne has received research grants from Abbott Diagnostics, Amarin, Amgen, Eli Lilly, Esperion, ISIS Pharmaceuticals, Novartis Pharmaceuticals, Pfizer, Otsuka, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, and Takeda Pharmaceuticals. He has also received consulting fees from Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Eli Lilly, Esperion, Genzyme, ISIS Pharmaceuticals, Matinas BioPharma Inc., Merck and Co., Novartis Pharmaceuticals, Pfizer, Regeneron, Roche, and Sanofi-Synthelabo.
    [Show full text]
  • Executive Profile: Genzyme's CEO on Dark Times, Transition and the Long
    June 15th 2015 scripintelligence.com Executive profile: Genzyme’s CEO on dark times, transition and the long view David Meeker, CEO of Sanofi company Genzyme, recently found himself hustling back to Genzyme’s Kendall Square offices from a nearby meeting to talk to Scrip’s editor Eleanor Malone about the challenges and opportunities he has encountered in his varied career. In the first of a two-part series, he discusses his experiences in the company that he joined in 1994, and expounds upon issues faced by the industry as a whole. Eleanor Malone: Genzyme went through some dark times before the Sanofi acquisition with the manufacturing issues that led to shortages of enzyme replacement therapies. What lessons did you draw from those difficulties? David Meeker: You are absolutely correct; they were incredibly painful, dark moments. We failed to deliver on the implicit promise David Meeker addresses employees at of ensuring that patients can access the Genzyme’s HQ following a torch relay connecting the company’s sites near Boston medicines that they need. I think we learned to mark International Rare Diseases Day many lessons. On a very tactical level we learned about the lead time that it takes to bring biologic manufacturing up – we realised it right for the patient, given the limitations Many acquisitions destroy value, and a lot too late that we were not going to be at an we had. We were short of product so we had of the destruction happens when people adequate capacity and by the time we started to focus on how to manage the distribution leave: you have the products but you lose to build, even though it was several years of that product in a way which was most the know-how and the critical talent that ahead of when we ran out of medicine, we equitable.
    [Show full text]
  • Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500
    Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500 www.dyax.com Other Offices Dyax SA, Liege, Belgium ADVANCING NOVEL THERAPEUTIC PRODUCTS Dyax Corp. Annual Report 2003 Corporate Information Dyax Achievements 2003 Dyax Goals 2004 Directors Executive Officers and Stock Listing Henry E. Blair Key Employees Common stock has been traded on the Nasdaq Stock Market Advances in Clinical Development Clinical Development Chairman, President and Henry E. Blair* under the symbol DYAX since our initial public offering in Milestones Chief Executive Officer, Chairman, President and August 14, 2000. DX-88/Hereditary Angioedema Dyax Corp. Chief Executive Officer DX-88/Hereditary Constantine E. Stephen S. Galliker, CPA* The following table gives the quarterly high and low sales G Completed 9-patient Phase II trial, met primary endpoints Angioedema Anagnostopoulos, Ph.D. EVP Finance and prices of our common stock for the last three years. G Genzyme Corporation joined Dyax as joint venture partner Managing General Partner, Administration and G Complete Phase II 2001 2002 2003 G Gateway Associates, LP Chief Financial Officer Completed 3 of 4 dose cohorts in 48-patient Phase II EDEMA1 trial EDEMA1 study High Low High Low High Low G Susan B. Bayh, J.D. Lynn G. Baird, Ph.D.* Initiated Phase II EDEMA2 trial G Periodically observe James W. Fordyce SVP Development First Quarter $20.94 $6.56 $11.38 $3.10 $2.25 $1.52 G Orphan Drug designation granted in U.S. and Europe effects of repeat dosing in Phase II EDEMA2 Managing Partner, Robert C. Ladner, Ph.D. Second Quarter $19.99 $6.81 $ 4.68 $3.20 $4.90 $1.67 Fordyce & Gabrielson, LLC SVP and Chief DX-88/On-Pump Open Heart Surgery (CABG) study Third Quarter $21.24 $6.05 $ 4.20 $1.65 $7.50 $2.58 Mary Ann Gray, Ph.D.
    [Show full text]
  • Cerezyme, INN-Imiglucerase
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Cerezyme 400 Units Powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 400 units* of imiglucerase**. After reconstitution, the solution contains 40 units (approximately 1.0 mg) of imiglucerase per ml (400 U/10 ml). * An enzyme unit (U) is defined as the amount of enzyme that catalyses the hydrolysis of one micromole of the synthetic substrate para-nitrophenyl β-D-glucopyranoside (pNP-Glc) per minute at 37°C. ** Imiglucerase is a modified form of human acid β-glucosidase and is produced by recombinant DNA technology using a mammalian Chinese Hamster Ovary (CHO) cell culture, with mannose modification for targeting macrophages. Excipients: For the full list of excipients, see section 6.1. This medicinal product contains sodium and is administered in 0.9% sodium chloride intravenous solution (see section 6.6). After reconstitution, the solution contains 1.24 mmol sodium (400 U/10 mL). To be taken into consideration by patients on a controlled sodium diet. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. Cerezyme is a white to off-white powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Cerezyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease after exclusion of other causes such as Vitamin D deficiency • hepatomegaly or splenomegaly 4.2 Posology and method of administration Disease management should be directed by physicians knowledgeable in the treatment of Gaucher disease.
    [Show full text]
  • Publication of Recordals of Assignment, Change of Name
    Publication of Recordals of Assignment, Change of Name, Merger and other Changes Affecting Title and Ownership of Granted Patents, Registered Utility Models, Industrial Designs and Lay-out Designs Topography) of Integrated Circuit Patent Number Title Patentee/Assignor Assignee/New Name Remarks 1199654059 COAXIAL ENGINE STARTER SYSTEM MITSUBA ELECTRIC MFG. CO. LTD. MITSUBA CORPORATION CHANGE OF NAME 31731 VALVE SYSTEM ISCOR LIMITED IPCOR NV ASSIGNMENT 25483 HERBICIDAL COMPOSITIONS ICI AMERICAS INC. ZENECA INC. CHANGE OF NAME 25483 HERBICIDAL COMPOSITIONS ZENECA INC. ZENECA AG PRODUCTS INC. ASSIGNMENT 1199142549 OXIME ETHERS DERIVATIVES NOVARTIS AG SYNGENTA PARTICIPATIONS AG ASSIGNMENT 1199142549 OXIME ETHERS DERIVATIVES SYNGENTA PARTICIPATIONS AG BAYER AKTIENGESELLSCHAFT ASSIGNMENT 31882 WATER SOLUBLE… GLAXO INC. GLAXO WELLCOME INC. CHANGE OF NAME 31882 WATER SOLUBLE… GLAXO WELLCOME INC. GILEAD SCIENCES, INC. ASSIGNMENT 31492 REPLACEABLE INTEGRATED… AMOS KORIN MIDWEST SCIENCES, INC. dba KORTECH, INC. ASSIGNMENT 31492 REPLACEABLE INTEGRATED… MIDWEST SCIENCES, INC. dba KORTECH, INC. PURE WATER FAMILY LIMITED PARTNERSHIP ASSIGNMENT 1199447817 GAS BURNER TRI-SQUARE INDUSTRIAL CO., LTD. HOSUN UNIVERSAL CO., LTD. CHANGE OF NAME 18495 LIQUID CRYSTAL DEVICES THE SECRETARY OF STATE FOR DEFENSE IN QINETIQ LIMITED ASSIGNMENT HER BRITTANIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN & NORTHERN IRELAND 31389 IMPROVEMENTS IN OR RELATING TO CATION… NATIONAL POWER PLC INNOGY LIMITED ASSIGNMENT 31389 IMPROVEMENTS IN OR RELATING TO CATION…
    [Show full text]
  • Concert Management
    CoNCERT Management Roger D. Tung President and Chief Executive Officer Roger D. Tung, Ph.D. is our scientific founder and has served as our President and Chief Executive Officer and as a mem- ber of our board of directors since April 2006. Before Concert, Dr. Tung was a founding scientist at Vertex Pharmaceuticals, a pharmaceutical company, where he was employed from 1989 to 2005, most recently as its Vice President of Drug Dis- covery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare pro- vider, and The Squibb Institute for Medicinal Chemistry. He also serves as a member of the University of Wisconsin- Madison School of Pharmacy’s Board of Visitors, faculty mentor in the MIT IMPACT program, and strategic advisor to Long- wood Founder’s Fund. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison. Marc Becker Chief Financial Officer Mr. Marc Becker has served as our Chief Financial Officer since January 2018. Prior to joining Concert, Mr. Becker served as Senior Vice President and Chief Financial Officer at CRISPR Therapeutics from February 2016 to September 2017. Prior to joining CRISPR Therapeutics, Mr. Becker served as Chief Financial Officer and Senior Vice President of rEVO Biologics, a biopharmaceutical from January 2012 to February 2016. Before rEVO, Mr. Becker spent 10 years at Genzyme Corpora- tion, most recently serving as Finance Director for the UK and Ireland before returning to the United States to become the Vice President of Finance for Genzyme’s Renal and Endocrine business.
    [Show full text]
  • PPCO Twist System
    Connect. Collaborate. Contribute. NOVEMBER 2016 Sanofi Genzyme: Expanding Beyond Rare Disease Into Specialty Care p. 18 David Meeker, executive VP and head, Sanofi Genzyme Clinical Trials 26 Allergan R&D 30 Biopharma 32 DC Insider 10 How A Chief Medical Officer Why The Company Women In Bio: Looking CEO Corner 12 Changed The Data-sharing Is Focusing On An Through The Glass Ceiling Culture At J&J And Across “Open-Science Platform” Companies To Watch 16 The Industry Global Update 48 Bringing together the best of When it’s YOUR compound, every step matters. www.pfizercentreone.com API DRUG PRODUCT PC1-16-0005-8.25x10.875 in-Mar., 2016 © 2016 Pfizer Inc. All rights reserved. inVentiv Health. Genetically engineered for success in the new pharmaceutical world. inVentiv Health processes and capabilities can accelerate business performance. The fact is, getting a new drug across the fi nish line is hard work every day. But lately, the challenges have increased exponentially. Today, it’s not enough to simply obtain regulatory approval; market success is now as mission-critical as trial success. Smart outsourcing partners begin with the end in mind. That’s why inVentiv purpose-built an organization in which both clinical and commercial work together under one roof as teammates and colleagues, not distant relatives. From early development through product launch, they share knowledge capital, data and insights. Our superior clinical trial design combined with highly effective commercial launch capabilities creates a unique environment in which processes and systems are constantly being challenged and evolved with an eye towards greater effi ciency, higher quality and, of course, getting to market faster.
    [Show full text]
  • Does M&A Create Value in the Pharmaceutical Sector?
    Does M&A create value in the pharmaceutical sector? A case study of the Sanofi-Aventis merger Silvia Cuasante López-Barrena HEC Paris – Majeure Finance June 2016 Research project supervised by Nicolas Naillon Silvia Cuasante López-Barrena May 2016 Table of Content Executive Summary ....................................................................................................................... 3 Structure of the Research Paper ................................................................................................... 4 Section I: Literature ....................................................................................................................... 5 1. Overview of the pharmaceutical industry ............................................................................. 5 1.1. Main players ................................................................................................................... 5 1.2. Product categories and pricing method ......................................................................... 6 1.3. Supply chain description ................................................................................................ 7 2. M&A and value creation ....................................................................................................... 8 2.1. In general terms ............................................................................................................. 8 2.2. In the pharmaceutical sector ......................................................................................
    [Show full text]
  • China Rare Disease Market: Large and Untapped Opportunity
    Delivering Life-Changing Therapies to Patients June 2019 Mission and Vision To be a global biopharmaceutical company delivering life-changing therapeutics built upon a foundation in China CANbridge Pharmaceuticals 2 Investment Highlights Pioneer in Balanced Leverage Comprehensive Deep, Advanced China’s Orphan Business Technology Global Solution Portfolio Drug Market Model Partnerships Provider Leadership: Foundation: Leverage Portfolio: Strategy: Mission: Sole Deputy Director near term revenue from 1 marketed, 2 near- Partner with leading To be a global General from industry oncology to support commercial, 5 rare academic institutions biopharmaceutical for China’s Alliance for orphan drug disease and 2 and biopharma company delivering Rare Disease (CARD) development oncology clinical companies life-changing candidates therapeutics built upon Experience: Future: Execution: a foundation in China CANbridge Team The premier partner for De-risked: Partnership with Wuxi launched first rare China and global rare Most candidates target and GC Pharma to disease drug in China disease drug commercially validated prosecute product development pathways candidates in China Visionary Management Team Thought leaders and political influencers directly involved in shaping the future of China’s orphan drug market CANbridge Pharmaceuticals 3 World Class Leadership Team with Deep Experience James Xue, Ph.D., M.B.A Ben Wu, M.B.A. • Brings significant orphan drug experience from across Asia Founder, Chairman, Head of Rare • Joined Genzyme in 2008 to pioneer
    [Show full text]
  • Exploring Technological Change in the German Pharmaceutical Industry
    Exploring technological change in the German pharmaceutical industry A history-friendly model of technological change and technology adoption in a science-based industry Zur Erlangung des akademischen Grades eines Doktors der Wirtschaftswissenschaften (Dr. rer. pol.) von der Fakultät für Wirtschaftswissenschaften der Universität Fridericiana zu Karlsruhe genehmigte Dissertation von lic. rer. pol. Iciar Dominguez Lacasa Tag der mündlichen Prüfung: 17. Juli 2005 Referent: Prof. Dr. Hariolf Grupp Koreferent: Prof. Dr. Hagen Lindstädt E R K L Ä R U N G (gemäß §4, Abs. 4 der Promotionsordnung vom 21. April 1989) Ich versichere wahrheitsgemäß, die Dissertation bis auf die in der Abhandlung angegebe Hilfe selbständig angefertigt, alle benutzten Hilfsmittel vollständig und genau angegeben und genau kenntlich gemacht zu haben, was aus Arbeiten anderer und aus eigenen Veröffentlichungen unverändert oder mit Abänderungen entnommen wurde. Acknowledgements The driving ideas for this project came from a working paper my supervisor gave me from the Danish Research Unit for Industrial Dynamics (DRUID). Already on the first pages I found a family of economic terms that were quite new for an economist with a strong neo-classical background like me: complex dynamics, behavioural patterns, invention, innovation, selection mechanisms, simulation model etc. Both, my curiosity to find out more about these terms and my interest for the economics of technological change motivated the learning process I have been involved in the last 4 years. This document is the result of this intellectual adventure. There are a number of people that have been important and I would like to thank here. First, I would like to express my special thanks to Hariolf Grupp for providing me with enough intellectual freedom and guidance when I needed it to complete this effort.
    [Show full text]
  • Client List LATEST
    Client number client name country area code client comments corporate number 1382 3 FHEA LAB AD GER SONER C11612 1017 3M MEDICAL DEPARTMENT USA ST PAUL 785 A.H. MARNE & CO LTD UK BRADFORD C11634 1781 ART JAPAN INC. JAP TOKYO 103 Applied Ananlytical Immagary Inc. 644 ABBOTT LABORATORIES LTD US ilILLINOIS Abbott Park C10042 1789 ACTIVE BIOTECH RESEARCH SWE LUND Lund Research Centre AB 1244 AGAN CHEMICAL ITA C10693 1245 AGOURON PHARMACEUTICALS INC. USA SAN DIEGO C10007 774 AGREVO UK LTD UK Now use 1849 Aventis CropScience 1302 AGRITECH UK LIMITED UK SELBOURNE C11646 619 AGRO KAHEAHO COMPANY LTD JAP TOKYO C10854 1773 AIR PRODUCTS AND CHEMICALS INC USA USA C10007 702 AJIMOMOTO CO INC JAP C10323 1946 AJIMOMOTO PHARMACEUTICALS EURO UK REDHILL EUROPE LTD 1043 AKED INTERVET NET C10211 1710 AKZO NOBEL SWE STENLUNGEUN C10210 254 ALBRIGHT & WILSON UK LIMITED UK HENLEY C11661 ALEEN LABORATORIES INC USA FORT WORTH C10663 1747 ALIZYME THERAPEUTICSLTD UK CAMBRIDGE C14475 ALLELEX BIO PHARMACEUTICALS CAN ONTARIO C14103 804 ALLERMAN UK C10903 2791 ALLERCENE LTD RAMAT ISRAEL 1725 ALLERGY THERAPEUTICS LTD UK WORTHING 635 ALMIRALL SPA BARCELONA C10320 1741 ALPHARMA AU NOR OSLO C23276 628 AMERICAN CYANAMID COMPANY USA C10016 1838 AMRAD OPERATIONS PTY LTD AUS RICHMOND C10135 1702 AMVAC CHEMICAL CORPORATIONUSA USA CITY OF CO City of COMMERCE, California C10814 1184 AMYLIN EUROPE LTD UK OXFORD C10020 1070 ANCARE NEW ZEALAND LTD NZ AUCKLAND 607 ANT. INTERNATIONAL LTD UK SUDBURY C11694 1622 ANTISEPTICA GmbH GER 1070 AORTECH EUROPE LTD UK LEEDS 1098 APHTON CORPORATION USA WOODLAND CITY C10916 1737 APOTEX RESEARCH INC. CAN ONTARIO C14502 1628 AQUAMARINE (LONDON) LTD UK HOUNSLOW 1711 ARIAD PHARMACEUTICALS INC USA MASS.
    [Show full text]
  • Annual Report on Form 20-F 2018
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boétie, 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boétie, 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one ordinary share, par value€2 per share NASDAQ Global Select Market Ordinary shares, par value€2 per share NASDAQ Global Select Market* Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2018 was: Ordinary shares: 1,245,454,385 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]